What is SpeechVive?
SpeechVive is at the forefront of assistive communication technology, offering a wearable speech device specifically engineered for individuals with Parkinson's disease. This innovative solution provides immediate enhancements to speech volume and clarity, serving as a powerful alternative to traditional, intensive therapy. The device's approval by Medicare and various insurance plans ensures broad accessibility, empowering patients to reclaim their voices and engage more fully in conversations, thereby dramatically improving their quality of life. The company's focus on tangible results and patient well-being positions it as a key player in healthcare innovation.
How much funding has SpeechVive raised?
SpeechVive has raised a total of $727K across 2 funding rounds:
Series A
$700K
Debt
$27K
Series A (2014): $700K with participation from Ambassador Enterprises, LLC
Debt (2021): $27K led by PPP
Key Investors in SpeechVive
Ambassador Enterprises, LLC
Ambassador Enterprises, LLC is a private equity firm focused on creating lasting positive impact. Their investment in SpeechVive suggests a strategic alignment with companies that demonstrate strong potential for both financial returns and significant societal benefit in the healthcare sector.
PPP
Public-Private Partnership
What's next for SpeechVive?
With the recent influx of substantial expansion capital, SpeechVive is poised for significant scaling and further development. The company's strategic focus will likely involve broadening its market reach, enhancing its product offerings, and potentially exploring new therapeutic applications for its technology. Continued investment in research and development, coupled with strategic partnerships, will be crucial for solidifying its market leadership and addressing the evolving needs of patients with speech impairments.
See full SpeechVive company page
